2 results
Approved WMOWill not start
To improve overall survival of patients with a early-stage high grade uterine leiomyosarcoma.
Approved WMOWill not start
Primary ObjectiveTo evaluate the preliminary safety and tolerability and the preliminary efficacy of cobimetinib administered as single agent (Arm A), cobimetinib + venetoclax (Arm B), and cobimetinib + venetoclax + atezolizumab (Arm C)Secondary…